Compound information
- Natural Products
- ZC1293702
- Molecular Formula
- C23H31N3O4S
- Molecular Weight
- 445.203527472 g/mol
- Structure
-
- IUPAC Name
- (E)-3-[4-(azepan-1-ylsulfonyl)phenyl]-1-[4-(cyclopropanecarbonyl)piperazin-1-yl]prop-2-en-1-one
- InChI
- InChI=1S/C23H31N3O4S/c27-22(24-15-17-25(18-16-24)23(28)20-8-9-20)12-7-19-5-10-21(11-6-19)31(29,30)26-13-3-1-2-4-14-26/h5-7,10-12,20H,1-4,8-9,13-18H2/b12-7+
- InChI Key
- RUCBKAJLKYHOPW-KPKJPENVSA-N
- SMILES
- O=C(/C=C/c1ccc(S(=O)(=O)N2CCCCCC2)cc1)N1CCN(C(=O)C2CC2)CC1
- Source
- ZINC000014142126
Warheads
- Cyclopropane
-
ADMET Property
Physicochemical Property
| Property | Value | Property | Value |
|---|---|---|---|
| Heavy Atom Count | 31 | Ring Count | 4 |
| Heteroatom Count | 8 | Rotatable Bond Count | 5 |
| Hydrogen Bond Acceptor Count | 4 | Hydrogen Bond Donor Count | 0 |
| Topological Polar Surface Area | 78.0 Å2 | LogP | 2.778 |
| LogS | -3.957 | LogD | 3.518 |
Absorption
| Property | Value | Property | Value |
|---|---|---|---|
| Pgp inhibitor | 0.014 | Pgp substrate | 0.979 |
| HIA | 0.968 | F20 % | 0.993 |
| F30 % | 0.702 | Caco-2 | -4.572 |
| MDCK | -4.924 |
Distribution
| Property | Value | Property | Value |
|---|---|---|---|
| BBB Penetration | 0.964 | PPB | 94.821 |
| VD | 0.947 | Fu | 1.181 |
Metabolism
| Property | Value | Property | Value |
|---|---|---|---|
| CYP1A2 inhibitor | 0.017 | CYP1A2 substrate | 0.372 |
| CYP2A6 substrate | 0.29 | CYP2B6 substrate | 0.656 |
| CYP2C19 inhibitor | 0.181 | CYP2C19 substrate | 0.595 |
| CYP2C8 substrate | 0.591 | CYP2C9 inhibitor | 0.189 |
| CYP2C9 substrate | 0.36 | CYP2D6 inhibitor | 0.08 |
| CYP2D6 substrate | 0.48 | CYP2E1 substrate | 0.308 |
| CYP3A4 inhibitor | 0.144 | CYP3A4 substrate | 0.965 |
Excretion
| Property | Value | Property | Value |
|---|---|---|---|
| T1/2 | 0.281 | CL | 3.55 |
Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| hERG Blockers | 0.127 | Hepatotoxicity | 0.588 |
| Mutagenicity | 0.004 | Rat Oral Acute Toxicity | 0.798 |
| FDAMDD | 0.802 | Skin Sensitization | 0.008 |
| Carcinogenicity | 0.039 | Eye Corrosion | 0.001 |
| Eye Irritation | 0.049 | Respiratory Toxicity | 0.093 |
Environmental Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| Bioconcentration Factors | 0.4 | IGC50 | 4.164 |
| LC50FM | -14.457 | LC50DM | -0.752 |
Tox21 Pathway
| Property | Value | Property | Value |
|---|---|---|---|
| NR-AR | 0.121 | NR-AR-LBD | 0.37 |
| NR-AhR | 0.038 | NR-Aromatase | 0.234 |
| NR-ER | 0.531 | NR-ER-LBD | 0.509 |
| NR-PPAR-gamma | 0.249 | SR-ARE | 0.776 |
| SR-ATAD5 | 0.548 | SR-HSE | 0.202 |
| SR-MMP | 0.028 | SR-p53 | 0.103 |
Similar covalent drugs
No similar covalent drugs found for this compound.